Insuman Rapid GT - Instructions, Use Of A Syringe Pen, Price, Analogues

2024 Author: Rachel Wainwright | [email protected]. Last modified: 2023-12-15 07:39

Insuman Rapid GT

Insuman Rapid GT: instructions for use and reviews

1. 1. Release form and composition
2. 2. Pharmacological properties
3. 3. Indications for use
4. 4. Contraindications
5. 5. Method of application and dosage
6. 6. Side effects
7. 7. Overdose
8. 8. Special instructions
9. 9. Application during pregnancy and lactation
10. 10. In case of impaired renal function
11. 11. For violations of liver function
12. 12. Use in the elderly
13. 13. Drug interactions
14. 14. Analogs
15. 15. Terms and conditions of storage
16. 16. Terms of dispensing from pharmacies
17. 17. Reviews
18. 18. Price in pharmacies

Latin name: Insuman Rapid GT

ATX code: A10AB01

Active ingredient: human insulin (Insulin human)

Producer: Sanofi-Aventis Vostok (Russia), Sanofi-Aventis Deutschland, GmbH (Sanofi-Aventis Deutschland, GmbH) (Germany)

Description and photo updated: 2018-29-11

Prices in pharmacies: from 1156 rubles.

Buy

Insuman Rapid GT is a short-acting human insulin.

Release form and composition

Dosage form - solution for injection: colorless, transparent (5 ml in colorless glass vials, in a cardboard box 5 bottles; 3 ml in cartridges made of colorless glass, 5 cartridges in a blister contour packaging, in a cardboard box 1 package; 3 ml each in cartridges made of colorless glass, mounted in disposable SoloStar pen-pens, in a cardboard box of 5 syringe-pens; each box also contains instructions for the use of Insuman Rapid GT).

Composition of 1 ml solution:

• active substance: soluble insulin (human genetically engineered) - 100 IU (International units), which corresponds to 3.571 mg;
• auxiliary components: water for injection, glycerol 85%, sodium dihydrogen phosphate dihydrate, m-cresol (m-cresol), as well as hydrochloric acid and sodium hydroxide (to adjust the pH).

Pharmacological properties

Pharmacodynamics

The active substance of the hypoglycemic drug Insuman Rapid GT is soluble insulin, obtained by genetic engineering using the K12 strain of E. coli, is identical in structure to human insulin.

The drug lowers the concentration of glucose in the blood, reduces catabolic effects and promotes the development of anabolic effects. Increases the transport of glucose and potassium into cells, lipogenesis in the liver and adipose tissue, the formation of glycogen in muscles and liver. Inhibits lipolysis, glycogenolysis and gluconeogenesis. Improves the utilization of pyruvate. Enhances protein synthesis and the flow of amino acids into cells.

Insuman Rapid GT is an insulin preparation with a fast onset and short duration of action. The hypoglycemic effect after subcutaneous (subcutaneous) administration develops within 30 minutes, reaches a maximum after 1–4 hours, and lasts for 7–9 hours.

Pharmacokinetics

Information on the pharmacokinetics of Insuman Rapid HT is not provided by the manufacturer.

Indications for use

• therapy of diabetes mellitus requiring the use of insulin;
• treatment of ketoacidosis and diabetic coma;
• achievement of metabolic compensation in patients with diabetes mellitus during surgical interventions (before and during surgery, as well as in the postoperative period).

Contraindications

The use of Insuman Rapid GT is contraindicated in patients with hypoglycemia and hypersensitivity to any component of the drug (active or auxiliary).

In the following cases, the drug should be used with caution (careful monitoring of the patient's condition is required, an adjustment of the insulin dose may be required):

• renal / hepatic impairment;
• proliferative retinopathy, especially in patients who have not received photocoagulation (laser therapy) treatment;
• intercurrent diseases;
• severe stenosis of the coronary / cerebral arteries;
• elderly age.

Insuman Rapid GT, instructions for use: method and dosage

There are no strictly regulated rules for dosing insulin. The drug, target blood glucose concentration, dosing regimen (dose and time of administration) are determined and adjusted by the attending physician for each patient, taking into account his diet, lifestyle and level of physical activity.

The average daily dose is 0.5-1 IU / kg, while 40-60% of the total required daily dose of insulin is the proportion of human insulin with prolonged action.

Insuman Rapid HT is injected deeply subcutaneously 15–20 minutes before meals, alternating injection sites within the same anatomical area of administration. Changing the injection site (for example, from the abdomen to the thigh) is possible only in consultation with the doctor, since there is a risk of a decrease in the absorption of insulin and, as a consequence, its hypoglycemic effect.

If necessary, it is allowed to inject Insuman Rapid HT intravenously (i.v.), however, in this case, treatment is carried out in a hospital or in another place, but subject to providing similar treatment and monitoring conditions.

Immediately before the set / introduction, the solution should be examined - it must be absolutely transparent and colorless, without visible foreign inclusions. If the drug has a different appearance, it cannot be used.

Insuman Rapid GT is prohibited for use in a variety of insulin pumps (including implanted ones) that contain silicone tubes.

The drug should not be mixed with animal insulins, insulins of a different concentration, insulin analogs and any other drugs.

It is allowed to mix Insuman Rapid GT with all human insulin preparations produced by the same company (Sanofi-Aventis).

To administer the drug, use only disposable plastic syringes of the appropriate concentration - when using 5 ml vials, OptiPen Pro1 or KlikSTAR syringe pens - when using 3 ml cartridges.

Each patient should be given clear instructions on the frequency of blood glucose testing and recommendations on the dosage regimen for Insuman Rapid HT in case of any changes in lifestyle or diet.

In severe hyperglycemia and ketoacidosis, the use of insulin is an indispensable component of complex therapy, which also includes measures to protect the patient from possible serious complications due to an intensive decrease in blood glucose levels. The treatment regimen requires careful monitoring in the intensive care unit, which includes monitoring the vital signs of the body, determining metabolic status, electrolyte balance and acid-base balance.

Dosing regimen correction

Dose change of Insuman Rapid GT may be required in the following cases:

• improved metabolic control (increased sensitivity to insulin, due to which the body's need for it decreases);
• changes in the patient's body weight or lifestyle, including the level of physical activity, diet, etc.;
• other circumstances, under the influence of which the predisposition to the development of hypo- or hyperglycemia may increase;
• elderly age;
• renal failure.

Switching to Insuman Rapid HT from another type of insulin

Dose adjustment of Insuman Rapid HT may be required in the following cases: switching from insulin of animal origin, switching from another type of human insulin, switching from insulin of a different duration of action.

When transferring a patient to Insuman Rapid HT from insulin of animal origin, it may be necessary to reduce the dose of the drug, especially for patients who have a tendency to develop hypoglycemia; previously required high doses of insulin due to the presence of antibodies to it; previously were conducted at fairly low blood glucose concentrations.

Reducing the dose of the drug may be required both immediately after changing the type of insulin, and after a few weeks. Thus, immediately after replacing the previous insulin with Insuman Rapid HT and in the first weeks of its use, it is recommended to provide the patient with careful monitoring of the state and concentration of glucose in the blood. Patients who received high doses of insulin due to the presence of antibodies should replace the drug in a hospital setting, since there is an opportunity to provide more careful medical supervision.

Application of Insuman Rapid GT in vials

1. Remove the plastic cap from the new bottle.
2. Draw air into the syringe in a volume equal to the required dose of insulin, and inject it into the vial (not into the solution).
3. Without removing the syringe, turn the bottle upside down and take the prescribed dose of insulin.
4. Remove air bubbles from the syringe.
5. Take a fold of skin at the injection site, insert the needle under the skin, and slowly inject insulin.
6. Remove the needle and press the injection site with a cotton swab for a few seconds.
7. Record the date of the first set of insulin from the vial on the vial label.

Application of Insuman Rapid GT in cartridges

Insulin in cartridges is intended for use with OptiPen Pro1 and KlikSTAR syringe pens. Before inserting, the cartridges should be kept at room temperature for 1–2 hours, since injections of the refrigerated preparation are painful. Before injection, air bubbles must be removed from the cartridge.

Cartridges are not intended to be mixed with other types of insulin and are not intended to be reused.

In the event of a breakdown of the syringe pen, the required dose of the drug from the cartridge can be administered using a conventional disposable syringe designed for a given concentration of insulin.

Once installed, the cartridge can be used for 4 weeks.

Each time after installing a new cartridge before the injection of the first dose, the correct operation of the syringe pen should be checked.

Application of Insuman Rapid GT in the SoloStar syringe pen

Insuman Rapid GT solution in the SoloStar pen can only be injected subcutaneously.

Before the first use, the syringe pen must be kept for 1-2 hours at room temperature. Before each use, you should inspect the cartridge inside the syringe pen to ensure that the condition of the solution is correct.

Used syringe pens must be destroyed because they are not intended for repeated use.

To avoid infection, only one patient should use each pen.

Information on using the SoloStar syringe pen:

• use needles that are compatible with SoloStar;
• use a new needle every time and conduct a safety test;
• take special precautions to prevent accidents involving the use of the needle and the possibility of transmission of infection;
• do not use a pen in case of damage or doubts about its correct operation;
• always have a spare pen in case of loss or damage to the main one;
• protect the pen from dirt and dust (from the outside, wipe with a clean damp cloth, do not rinse, do not lubricate or immerse in a liquid, so as not to damage).

Application of the SoloStar syringe pen:

1. Insulin control: Before the first use, it is recommended to check the label on the pen to ensure the correct type of insulin is selected. The SoloStar syringe-pen intended for the preparation Insuman Rapid GT, white with a yellow button and a relief ring on it. After removing the cap, you need to check the appearance of the solution contained in the syringe pen for transparency, colorlessness and the absence of foreign particles.
2. Needle attachment: It is important to use only compatible needles. A new sterile needle must be installed for each injection. Insert the needle carefully after removing the cap.
3. Conducting a safety test (it is necessary to perform a test before each injection to make sure that the syringe pen and needle are working, as well as that there are no air bubbles): after removing the outer and inner caps, measure the dose of 2 units, position the syringe pen with the needle up and gently knock finger on the cartridge so that all air bubbles are directed to the needle, and press the yellow button. If the solution appears at the tip of the needle, then the syringe pen with the needle is working correctly. If the drug does not appear, the entire procedure should be repeated until insulin appears at the tip of the needle.
4. Dose selection: on the SoloStar syringe pen, you can set the dose with an accuracy of 1, from the minimum (1 unit) to the maximum (80 units). If an even higher dose is needed, 2 or more injections are given. At the time of choosing the prescribed dose, the number "0" should be displayed in the dosage window.
5. Dose administration: it is necessary to insert the needle under the skin and fully press the yellow button. For 10 seconds, keep the button pressed and do not remove the needle to ensure that the selected dose of insulin is fully delivered.
6. Needle removal and disposal: Needles should be removed and discarded after each injection. To avoid the risk of accidents and to prevent infection, it is important to take special precautions (for example, putting on the cap with one hand). After removing the needle, it is necessary to close the syringe pen with a cap.

Before using the SoloStar syringe pen for the first time, it is recommended that you read the instructions for its use.

Side effects

The most common side effect of insulin therapy is hypoglycemia. It develops most often in cases when the dose of the administered Insuman Rapid HT exceeds the body's need for insulin. With repeated severe episodes, neurological symptoms may develop, including seizures and coma. Severe and prolonged episodes are potentially life-threatening for the patient.

The manifestations of neuroglycopenia in many patients are preceded by symptoms of reflex activation of the sympathetic nervous system (in response to developing hypoglycemia), which can be pronounced with a more rapid or more pronounced decrease in blood glucose levels. A sharp decrease in glucose can cause the development of hypokalemia (a complication of the cardiovascular system) and cerebral edema.

Other possible side effects (classification by frequency of occurrence: often - from ≥ 1/100 to <1/10, infrequently - from ≥ 1/1000 to <1/100, unknown frequency - it is not possible to establish the frequency based on available data):

• allergic reactions: infrequently - anaphylactic shock; unknown frequency - bronchospasm, angioedema, generalized skin reactions, the formation of antibodies to insulin. Allergic reactions of an immediate type to any component of the drug Insuman Rapid HT require urgent emergency measures;
• from the side of metabolism and nutrition: often - edema; unknown frequency - sodium retention (these phenomena more often occur with the improvement of previously insufficient metabolic control due to more intensive insulin therapy);
• on the part of the cardiovascular system: unknown frequency - decrease in blood pressure;
• on the part of the skin and subcutaneous tissues: unknown frequency - lipodystrophy at the injection site and a slowdown in local absorption of insulin (this side effect can be prevented by constantly changing injection sites within the indicated injection area);
• on the part of the organ of vision: unknown frequency - a temporary worsening of the course of diabetic retinopathy (due to more intensive insulin therapy with a sharp improvement in glycemic control), transient visual disturbances (due to a temporary change in the turgor of the lenses of the eyes and their refractive index); in patients with proliferative retinopathy - transient amaurosis (especially in cases where laser therapy is not performed);
• local reactions: unknown frequency - pain, redness, swelling, hives, itching, inflammation at the injection site (usually disappear after a few days or weeks).

Overdose

Insulin overdose leads to hypoglycemia, sometimes severe, prolonged and even life-threatening.

With mild episodes of hypoglycemia, the patient is conscious, so he can independently stop them by taking carbohydrates. For moderate episodes, intramuscular / subcutaneous administration of glucagon or intravenous administration of a concentrated dextrose solution is required (the dose for children is calculated depending on body weight). After the blood glucose level rises, the doctor may recommend a maintenance carbohydrate intake, and medical supervision is also required, as there is a risk of a second episode. For severe and prolonged hypoglycemia, a less concentrated dextrose solution is usually infused after glucagon or dextrose administration to prevent a recurrence of the episode. Especially close supervision (including glucose monitoring) is required in young children, as they are at risk of severe hyperglycemia.

In certain situations, it is necessary to hospitalize the patient in the intensive care unit in order to more closely monitor the patient's condition and monitor the effectiveness of the therapy.

In the future, the patient may need to adjust the dose of Insuman Rapid HT, the regimen of food intake and / or physical activity.

special instructions

In many diabetic patients with hypersensitivity to insulin of animal origin, the transition to human insulin is difficult due to cross-immunological reactions. In patients with hypersensitivity to animal insulin or m-cresol, the tolerance of Insuman Rapid HT is assessed in the clinic by means of intradermal tests. If the test results show an immediate reaction (for example, Arthus reaction), treatment with this drug can only be carried out under close clinical monitoring.

If the use of Insuman Rapid HT does not provide proper glycemic control, as well as in cases where there is a tendency to develop episodes of hypo- or hyperglycemia, the doctor decides to adjust the dose of the drug. However, before that, he must check the patient's compliance with the prescribed treatment regimen (including adherence to the insulin dosing regimen, the correct choice of the injection site and its implementation) and take into account the possible presence of factors that may affect the hypoglycemic effect of insulin.

No medications should be taken without the agreement of the attending physician, since when used simultaneously, they can change the action of Insuman Rapid HT (increase or decrease).

A common side effect of insulin therapy is hypoglycemia, which develops when the dose of insulin exceeds the need for it. The risk is highest at the beginning of insulin use, when switching to another type / preparation of insulin, and when maintenance blood glucose levels are low.

With extreme caution and under intensive glucose control, treatment with Insuman Rapid HT should be carried out in patients for whom hypoglycemic episodes may be of particular danger. For example, with severe stenosis of the cerebral or coronary arteries, hypoglycemia can cause cerebral or cardiac complications, with proliferative retinopathy (especially in patients not receiving photocoagulation treatment) against the background of hypoglycemia, transient amaurosis (complete blindness) may develop.

Factors that increase the predisposition to the development of episodes of hypoglycemia require careful monitoring and, possibly, correction of the insulin dose:

• skipping meals;
• insufficient food intake;
• unusual physical activity (increased or prolonged);
• some uncompensated endocrine diseases (for example, hypothyroidism, insufficiency of the adrenal cortex, insufficiency of the anterior pituitary gland);
• intercurrent pathology (vomiting, diarrhea);
• alcohol consumption;
• the simultaneous use of certain drugs;
• increasing insulin sensitivity (for example, eliminating stressors);
• changing the area of insulin injection.

Some clinical symptoms and signs may indicate developing hypoglycemia, such as moisture and pallor of the skin, excessive sweating, sleep disturbances, drowsiness, anxiety, unusual behavior, irritability, impaired coordination of movements, headache, tremors, depression, fear, transient neurological disturbances (speech / vision disorders, paralytic symptoms), hunger, increased blood pressure, tachycardia, chest pain, heart rhythm disturbances, paresthesia in the mouth and around the mouth, as well as unusual sensations. If the decrease in glucose concentration continues, the patient may lose self-control and even consciousness.

Each patient should be trained by the physician to recognize symptoms that indicate increasing hypoglycemia. The risk of developing episodes is lower in people who regularly monitor their blood glucose levels. Patients who notice a decrease in glucose concentration themselves can correct this condition by eating carbohydrate-rich foods or sugar (it is recommended to always carry 20 g of glucose with you). In more severe conditions, subcutaneous administration of glucagon is indicated (the injection should be done by a doctor or nursing staff). After a sufficient improvement in the condition, the patient is given food. In case of hypoglycemia, which cannot be immediately eliminated, an ambulance must be called urgently. The attending physician should be informed about the development of the episode so that, if necessary, he can adjust the dose of Insuman Rapid HT.

Skipping insulin injections, decreased physical activity, non-compliance with a diet, increased need for insulin due to an infectious or other disease - in all these cases there is a risk of developing hyperglycemia, including with ketoacidosis, which can develop both within a few hours and over several days. As soon as the patient notes the first signs of metabolic acidosis (thirst, loss of appetite, frequent urination, dry skin, fatigue, rapid and deep breathing, high concentrations of acetone and glucose), he should immediately seek medical help.

The physician should warn each patient that the symptoms indicating an increase in hypoglycemia may change, be less pronounced or completely absent under some conditions. These include:

• the gradual development of hypoglycemia;
• significant improvement in glycemic control;
• long history of diabetes mellitus;
• the presence of autonomic neuropathy;
• the simultaneous use of certain medicines;
• elderly age.

Under such circumstances, it is possible for a severe hypoglycemic episode (including loss of consciousness) to develop before the patient realizes his condition. It should be assumed that there is a risk of recurrent, unrecognized (especially nocturnal) episodes of hypoglycemia in patients with normal or decreased glycosylated hemoglobin values.

The risk of hypoglycemic episodes is significantly lower in case of strict adherence to the prescribed dosage regimen of Insuman Rapid HT and the diet, correct administration of injections.

If the patient has an intercurrent disease, intensive metabolic control is necessary. For many people, urinalysis for ketone bodies is indicated. In most cases, a dose adjustment of Insuman Rapid HT is required, since the need for insulin increases. In type 1 diabetes, patients should continue to take at least a small amount of carbohydrates regularly, even if they can only eat a small amount of food or are vomiting. Insulin administration should not be stopped completely.

In the event of a change of doctor (for example, when hospitalized due to an accident or illness while on vacation), the patient must report the presence of diabetes mellitus.

Influence on the ability to drive vehicles and complex mechanisms

During the period of insulin therapy, due to side effects in the form of visual disorders, as well as as a result of developing hyper- or hypoglycemia, the reaction rate and the ability to concentrate may decrease. In circumstances where these functions are important (including driving and operating complex machinery), violations can pose a certain risk. Care must be taken during insulin treatment to prevent the development of hypoglycemia. These recommendations are especially important for patients in whom hypoglycemic symptoms are mild or absent, or episodes occur frequently. The ability to engage in potentially hazardous activities in these patients is determined by the doctor individually.

Application during pregnancy and lactation

Insuman Rapid HT should not be canceled at the onset of pregnancy, since insulin does not penetrate the placental barrier, and maintaining adequate metabolic control throughout pregnancy is imperative for both women with diabetes mellitus before pregnancy and women with gestational diabetes mellitus. The need for insulin usually decreases in the first trimester, rises in the second and third trimesters, and decreases rapidly again immediately after childbirth. It is necessary to carefully monitor the level of glucose in the blood, insulin therapy should be carried out under special medical supervision.

Lactation is not a contraindication to the use of insulin, however, correction of the diet and dosage regimen of Insuman Rapid GT is usually required.

With impaired renal function

In patients with impaired renal function, Insuman Rapid HT should be used with caution, since, due to a decrease in insulin metabolism, the body's need for it may decrease.

For violations of liver function

In patients with impaired liver function, Insuman Rapid HT should be used with caution, since due to a decrease in insulin metabolism, the body's need for it may decrease.

Use in the elderly

In elderly patients with diabetes mellitus, it is possible to reduce the need for insulin. The doctor should start insulin therapy, each dose increase and the selection of a maintenance dose of Insuman Rapid HT with caution, avoiding the development of hypoglycemic reactions.

Drug interactions

With the simultaneous use of the following drugs, a decrease in the hypoglycemic effect of insulin is possible: isoniazid, doxazosin, diazoxide, danazol, glucagon, phenolphthalein, corticotropin, somatotropin, nicotinic acid, thyroid hormones, diuretics, phenytoin derivatives, phenothiazine derivatives, including estrogens, estrogens and in oral contraceptives), barbiturates, sympathomimetic agents (eg epinephrine, salbutamol and terbutaline).

With the simultaneous use of the following drugs, it is possible to increase the hypoglycemic effect of insulin and an increase in the predisposition to hypoglycemia: oral hypoglycemic drugs, phentolamine, phenoxybenzamine, propoxyphene, trophosphamide, fenfluramine, cyclophosphamide, disopyramide, ifosfamide, guoquanetidine, tsitbritbritin and its analogs, monoamine oxidase inhibitors, salicylates, sulfonamides, fibrates, tetracyclines, angiotensin converting enzyme inhibitors, anabolic steroids and male sex hormones.

Sympatholytic agents (guanethidine, reserpine, clonidine, beta-blockers) can weaken or completely stop the symptoms of reflex activation of the sympathetic nervous system (in response to hypoglycemia).

With the combined use of pentamidine, there is a risk of hypoglycemia, sometimes turning into hyperglycemia.

Clonidine, beta-blockers and lithium salts can change the hypoglycemic effect of insulin (both weaken and potentiate).

Ethanol can increase or decrease the effect of insulin, cause hypoglycemia, or lower already low blood glucose levels to dangerous levels. In addition, in patients receiving insulin, ethanol tolerance is reduced. The amount of ethanol you can consume is determined by your doctor.

Analogs

The analogues of Insuman Rapid GT are: Actrapid NM, Actrapid NM Penfill, Apidra, Biosulin R, Vozulim-R, Insuran R, Monoinsulin CHR, Rinsulin R, Rosinsulin R, Humodar R 100, Humodar R 100 Rek, Humulin Regular.

Terms and conditions of storage

Store at a temperature of 2 to 8 ° C, protected from light, out of reach of children.

Shelf life is 2 years.

The opened bottle and the syringe pen with the cartridge installed can be stored at temperatures up to 25 ° C in a place protected from heat and light for 4 weeks. Do not refrigerate as cold insulin injections are more painful.

Terms of dispensing from pharmacies

Dispensed by prescription.

Reviews about Insuman Rapid GT

Positive feedback about Insuman Rapid GT is left by both doctors and patients. The drug effectively reduces the increased concentration of glucose in the blood, is well tolerated and does not cause adverse reactions. Additional advantages include an affordable price (comparable to analogues) and the availability of convenient forms of release - cartridges and ready-to-use syringe pens, which greatly simplify the dosage of insulin and the process of its administration.

Price for Insuman Rapid GT in pharmacies

Approximate prices for Insuman Rapid GT: 5 vials of 5 ml - 1059-1200 rubles, 5 cartridges of 3 ml - 1228 rubles, 5 SoloStar pens with cartridges of 3 ml - 1115-1228 rubles.

Insuman Rapid GT: prices in online pharmacies

Drug name Price Pharmacy

Insuman Rapid GT 100 IU / ml solution for injection 3 ml 5 pcs. 1156 RUB Buy

Maria Kulkes Medical journalist About the author

Education: First Moscow State Medical University named after I. M. Sechenov, specialty "General Medicine".

Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!